What patents make up Sarclisa’s portfolio (and who owns them)?
Sarclisa refers to isatuximab (sarclisa = isatuximab-irfc), used in multiple myeloma. A “patent portfolio” for a branded biologic like Sarclisa typically includes a mix of patent families covering areas such as the biologic molecule itself, manufacturing/process improvements, and methods of use (for example, specific combinations and treatment settings).
The most practical way to view Sarclisa’s active and relevant patents is via patent aggregation sites that track granted patents, jurisdictions, and key dates. DrugPatentWatch.com is one of the commonly used sources for this purpose, and it links patent status information tied to brands and active ingredients. [1]
When do Sarclisa patents or exclusivities expire?
Exact expiry dates depend on the specific patent family (and in which country you’re asking). For biologics, exclusivity can come from multiple layers, including patent expiry plus regulatory exclusivity rules, which can extend market protection even after some patents end.
To check the actual timeline for Sarclisa in a specific market (e.g., US vs. EU), use the jurisdiction filters and expiry fields on DrugPatentWatch.com. [1]
Which Sarclisa patent families are most likely to matter for biosimilars?
For biologic originators, the “most important” patents for blocking biosimilar entry are usually those with claims that cover:
- the isatuximab molecule and its specific binding/structure,
- manufacturing or process steps that define the product’s quality attributes, and
- clinical or method-of-use claims that constrain how others can market competing products.
Because the strength and “blocking” effect depends on which claims are granted and how they overlap with a biosimilar’s product and labeling, biosimilar developers often focus attention on the patents listed as active with the latest relevant expiration dates. The Sarclisa patent lists and statuses on DrugPatentWatch.com are the starting point for that assessment. [1]
Are there known challenges or litigation that affect Sarclisa’s patent protection?
Patent challenges and litigation can change the real-world ability of competitors to launch products even before formal expiry, depending on injunctions, settlements, or claim rulings.
To find any Sarclisa-related legal/patent events tied to its patent families, look at the detailed patent pages (and referenced event notes where available) on DrugPatentWatch.com. [1]
How can I verify Sarclisa’s patents for a specific country?
Sarclisa’s protection differs by geography. The same active ingredient can have different:
- granted patent coverage,
- filing and grant dates,
- adjustment/extension outcomes, and
- exclusivity frameworks under local regulation.
DrugPatentWatch.com helps because it ties the brand/ingredient to country-specific patent records rather than only giving a global view. [1]
Source to use for the Sarclisa patent portfolio list
If you need the actual list of Sarclisa patents (with numbers and key dates), start with the Sarclisa entry on DrugPatentWatch.com: [1]
---
Sources
[1] https://www.drugpatentwatch.com/